Nonandrogenic mediators of prostatic growth

Hematology/Oncology Clinics of North America

Volumn 15, Issue 3, 2001, Pages 459-476

  Konety, B R ^a   Nelson, J B ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA;

CANCER GROWTH; GROWTH REGULATION; HUMAN; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; REVIEW;

EID: 0034892592     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70226-4     Document Type: Article

References (130)

1. Growth factors and cancer
2. Comparative studies on testosterone and L-thyroxine effects on the sympathetic neurons: Effect of antiserum to nerve growth factor
3. Insulin like growth factor I (IGF-I) and its binding protein IGF-BP4 in human prostatic hyperplastic tissue: Gene expression and its cellular location
4. Mammary cancer in transgenic mice expressing insulin-like growth factor II
5. Growth regulatory properties of endothelins
6. Bombesin stimulates growth of human prostatic cancer cells in vitro
7. Anti-sense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
8. Peptide growth factors in the prostate as mediators of stromal epithelial interaction
9. Massive amounts of immunoreactive endothelin in human seminal fluid
10. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
11. Expression of mRNA for epidermal growth factor, transforming growth factor alpha and their receptor in human prostate tissue and cell lines
12. Characterization of the role of IL-6 in the progression of prostate cancer
13. The IGF axis in the prostate
14. Insulin like growth factors (IGF's), IGF receptors and IGF-binding proteins in primary cultures of prostate epithelial cells
15. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia
16. Prostate specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma
17. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease
18. Elevated levels of insulin-like growth factor binding protein-2 in the serum of prostate cancer patients
19. Serum insulin-like growth factor-1 levels and prostate cancer risk - Interpreting the evidence
20. Production of epidermal growth factor and transforming growth factor-α by the androgen responsive LNCaP human prostate cancer cell line
21. Secretion of epidermal growth factor and related polypeptides by the DU145 human prostate cell line
22. Effect of prolactin on the prostate
23. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase
24. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor
25. Interleukin-1 beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells
26. Keratinocyte growth factor as a mediator of mesenchymal-epithelial interactions in the development of androgen target organs
27. Human transforming growth factor-β complementary DNA sequences and expression in normal and transformed cells
28. Neuroendocrine differentiation in prostatic carcinoma
29. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2
30. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate
31. Role of nerve growth factor-like protein in the paracrine regulation of prostate growth
32. Prolactin and glucocorticoid hormones control transcription of the β-casein gene by kinetically distinct mechanisms
33. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer
34. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cells
35. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: Evidence for an IGF-II autocrine growth loop
36. Insulin-like growth factor-1 receptors in human hyperplastic tissue: Characterization, tissue localization and their modulation by chronic treatment with a gonadotrophin releasing analog
37. Peptide growth factors and prostate cancer. New models, new opportunities
38. Epidermal growth factor and prostatic carcinoma: An immunohistochemical study
39. Complex regulation of TGFβ expression by retinoic acid in the vitamin A deficient rat
40. Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma
41. Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy
42. Growth hormone and prostate cancer: Guilty by association?
43. Guinea pig prostate is a rich source of nerve growth factor
44. Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP
45. Androgenic regulation of epidermal growth factor in the mouse ventral prostate
46. Growth factors and their cellular action
47. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor
48. Growth modulation of human prostatic cancer cells by interleukin-1 and interleukin-1 receptor antagonist
49. Studies on prostatic cancer: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
50. Insulin-like growth factor I: Action and receptor characterization in human prostate cancer cell lines
51. Insulin-like growth factors and their binding proteins: Biological actions
52. Stromal cells of human prostate: Initial isolation and characterization
53. Expression and localization of transforming growth factor β receptors type I and type II in the rat ventral prostate during regression
54. Loss of expression of transforming growth factor-β receptors type I and type II correlates with tumor grade in human prostate cancer tissues
55. Inhibition of IGF-II stimulated growth of prostate cancer cells by IGF-I receptor specific monoclonal antibody and antisense oligonucleotide of IGF-II messenger RNA
56. Amplification of a novel v-erbB-related gene in human mammary carcinoma
57. Localization of endothelin receptors in the human prostate
58. Effect of retinoic acid on in vitro and in vivo growth of metastatic prostate cancer cells
59. The role of vitamin D in normal prostate growth and differentiation
60. Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture
61. Expression of the c-erbB-2 (HIER-2/neu)oncoprotein in human prostatic carcinoma
62. Expression of transforming growth factor β in the rat ventral prostate during castration induced programmed cell death
63. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation
64. Molecular and cellular biology of prostate cancer
65. Growth-hormone releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor-II tumors
66. Endotheli-1 in human prostate: Tissue levels, source of production and isometric tension studies
67. Molecular and cellular aspects of the insulin-like growth factor I receptor
68. The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma
69. Proliferating or interleukin 1 activated human vascular smooth muscle cells secrete copious interleukin 6
70. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines
71. Localization of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemical methods
72. Transforming growth factor-beta 2: cDNA cloning and sequence analysis
73. Endothelin and menstruation
74. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells
75. The transforming growth factor-beta family
76. Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia and benign hyperplasia
77. Heparin-binding growth factor/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type beta
78. The heparan sulfate fibroblast growth factor family: Diversity of structure and function
79. The human prostatic carcinoma cell line LNCaP expressed biologically active specific receptors for 1 alpha, 25 dihydroxyvitamin D3
80. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines
81. Infrequent RAS oncogene mutations in human prostate cancer
82. The int-2 gene product acts as an epithelial growth factor in transgenic mice
83. Heparin-binding growth factor isolated from human prostatic extracts
84. Insulin-like growth factor receptors
85. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer
86. Identification of endothelin-1 in the pathophysiology metastatic adenocarcinoma of the prostate
87. New bone formation in an osteoblastic tumor model is increased by Endothelin-1 overexpression and decreased by endothelin A receptor blockade
88. The role of the endothelin axis in prostate cancer
89. Transforming growth factor-beta and its actions on cellular growth and differentiation
90. Growth responses of normal, benign hyperplastic and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract and hydrocortisone
91. The role of insulin-like growth factors in prostate biology
92. Antiproliferative effects of 1,25-dihydroxy-vitamin D3 on primary cultures of human prostatic cells
93. Inhibition of growth of prostate cancer cell lines by peptide analogues of insulin-like growth factor I
94. Constitutive expression of insulin-like growth factor I and insulin growth factor 1 receptor abrogates all requirements for exogenous growth factors
95. Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells
96. Endothelins in the control of cardiovascular and renal function
97. Mechanisms by which prolactin and glucocorticoids regulate casein expression
98. Prognostic significance of HER-2/neu gene amplification status by fluorescent in situ hybridization of prostate carcinoma
99. Changing pattern of expression of epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms
100. Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones
101. Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids
102. Effect of Bombesin and its antibody on human prostatic carcinoma cell lines (DU145, PC-3)
103. Hematopoietic growth factors
104. Dietary fenretinamide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras + myc induced carcinomas in the mouse prostate reconstitution model system
105. Endothelin immunoreactivity of airway epithelium in asthmatic patients
106. Transforming growth factor-beta 1 overproduction in prostate cancer: Effects on growth in vivo and in vitro
107. Review of peptide growth factors in benign prostatic hyperplasia and urologic malignancy
108. Influence of transforming growth factor beta I and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts
109. Prostatic growth factor: Purification and structural relationship to basic fibroblast growth factor
110. Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor
111. Polypeptide modulators of prostate growth and development
112. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha LPS and IL-1 beta
113. Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate
114. Interaction of epidermal growth factor and transforming growth factor-β1 in human prostatic epithelial cells in culture
115. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae
116. Transforming growth factor alpha and its receptor are expressed in the epithelium of the rat prostate gland
117. Protein and messenger ribonucleic acid (mRNA) for the type I insulin-like growth factor (IGF) receptor is decreased and IGFII mRNA is increased in human prostate carcinoma compared to benign prostate epithelium
118. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia and adenocarcinoma of the prostate
119. Mesenchymal-epithelial interactions and transforming growth factor-β expression during mouse prostate morphogenesis
120. Prostatic epidermal growth factor receptors and their regulation by androgens
121. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer
122. Growth factors and their receptors as determinants in the proliferation and metastasis of prostate cancer
123. Calcium signaling in prostate cancer cells: Evidence for multiple receptors and enhanced sensitivity to Bombesin/GRP
124. Response of prostate cancer cells to peptide growth factor: Transforming growth factor-β
125. Mechanism of activation of the TGF-β receptor
126. Heparin-binding keratmocyte growth factor is a candidate stromal to epithelial cell andromedin
127. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy
128. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
129. Prolactin stimulates transcription of growth-related genes in NB2 T lymphoma cells
130. Expression of c-erbB-2/neu proto-oncogene in human prostatic cancer cell tissues and cell lines